<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854838</url>
  </required_header>
  <id_info>
    <org_study_id>2019-FXY-020</org_study_id>
    <nct_id>NCT03854838</nct_id>
  </id_info>
  <brief_title>IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.</brief_title>
  <official_title>A Single Center 、Single Arm Phase I/II Clinical Trial of Intensity-modulated Radiotherapy Combined With Toripalimab in the Treating of Unresectable Locally Recurrent Nasopharyngeal Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of intensity-modulated
      radiation therapy combined with toripalimab in patients with the unresectable locally
      recurrent nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label ,single center ,non-randomized, single arm exploratory study. All
      eligible patients presented with non-keratinizing NPC and stage rT0-4N1-3M0 /rT2-4N0M0 are
      assigned to receive IMRT combined with toripalimab.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression-Free Survival is defined as time interval from recruitment to tumor progression or censoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall Survival is defined as time interval from recruitment to all-caused death or censoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Through study completion, an average of half a year</time_frame>
    <description>Adverse events (AE), Serious Adverse Event(SAE)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Nasopharyngeal Neoplasms</condition>
  <condition>Nasopharyngeal Diseases</condition>
  <condition>Head and Neck Neoplasm</condition>
  <arm_group>
    <arm_group_label>Toripalimab +Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy, intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks ) will be administered as an intravenous infusion over 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolipalimab</intervention_name>
    <description>Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.</description>
    <arm_group_label>Toripalimab +Radiotherapy</arm_group_label>
    <other_name>JS001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Reirradiation</intervention_name>
    <description>intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks</description>
    <arm_group_label>Toripalimab +Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed Recurrent Nasopharyngeal Carcinoma ( the recurrence time was
             more than 12 months from the end of the first course of radiotherapy)

          2. Patients with histologically confirmed nasopharyngeal carcinoma(WHO type II-III)

          3. Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria;

          4. Can provide either a newly obtained or archival tumor tissue sample.

          5. Tumor staged as rT0-4N1-3M0 or T2-4N0M0，II-IVa (according to the 8th AJCC edition).

          6. 18 Years to 65 Years

          7. Eastern Cooperative Oncology Group performance status ≤1

          8. Adequate marrow function: neutrocyte count≥1.5×10e9/L, hemoglobin ≥90g/L and platelet
             count ≥100×10e9/L.Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST)
             ≤2.5×upper limit of normal (ULN), and bilirubin ≤ 1.5×ULN. Adequate renal function:
             creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula).

          9. Life expectancy ≥ 3months

         10. Subjects must be willing to participate in the research and sign an informed consent
             form (ICF)

         11. Female of child bearing potential, a negative urine or serum pregnancy test result
             within 72 h before study treatment. Participants of reproductive potential must be
             willing to use adequate contraception for the course of the study through 60 days
             after the last dose of Toripalimab.

         12. Male subjects with WOCBP partner must be willing to use adequate contraception for the
             course of the study through 120 days after the last dose of Toripalimab.

        Exclusion Criteria:

          1. operable recurrence of nasopharyngeal cancer: rT1N0M0 rT2N0M0 (the tumour was confined
             in the superficial parapharyngeal spacer) rT3N0M0 (the tumour was confined in the base
             wall of the sphenoid sinus) rT0N1-3M0 (the tumour was not invasion into the cervical
             vertebrae, brachial plexus, deep muscles of the neck, or carotid artery)

          2. Has known allergy to large molecule protein products or any compound of study therapy

          3. Has known Subjects with other malignant tumors

          4. Has any active autoimmune disease or history of autoimmune disease

          5. Has a history of psychiatric substance abuse, alcoholism, or drug addiction;

          6. the laboratory examination value does not meet the relevant standards within 7 days
             before enrollment

          7. Received a systematic Glucocorticoid therapy within 4 weeks of the first dose of study
             medication.

          8. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with
             adequately treated active TB with 1 year.

          9. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent;

         10. Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis,
             nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy)
             Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo,
             psoriasis, or alopecia) will be allowed to enroll.

         11. Has a known history of human immunodeficiency virus (HIV).

         12. Has hepatitis B surface antigen (HBsAg) positive or hepatitis C virus (HCV) antibody
             positive

         13. Has received a live vaccine within 4 weeks of planned start of study therapy

         14. Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Yuan Chen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Yuan Chen, MD,PhD</last_name>
    <phone>+86-20-87343361</phone>
    <email>chenmy@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Yuan Chen, MD,PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 24, 2019</study_first_submitted>
  <study_first_submitted_qc>February 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>March 21, 2020</last_update_submitted>
  <last_update_submitted_qc>March 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming-Yuan Chen</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>toripalimab</keyword>
  <keyword>IMRT</keyword>
  <keyword>Intensity-Modulated Radiation Therapy</keyword>
  <keyword>PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

